ARGX ▲ +4.6% - argenx SE
$ARGX - argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis
07-NOV-2026 10:01 AM ET
Share this post
More filings for $ARGX
ARGX - argenx SE - SEC Filing Update (05-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 5, 2026ARGX ▼ -2.0% - argenx SENov 3, 2026ARGX ▼ -0.4% - argenx SEOct 19, 2026ARGX ▼ -0.2% - argenx SEOct 8, 2026ARGX ▼ -0.2% - argenx SEOct 8, 2026ARGX ▼ -0.1% - argenx SESep 29, 2026
View full $ARGX filing history →💬 Comments
Loading comments…
Leave a comment